Relationship between VMAT2-PET and DAT-SPECT caudate binding and Parkinson's disease cognitive decline

Area of Science:

• Neuroimaging
• Neurology
• Molecular Imaging

Background:

• Dopamine transporter (DAT) imaging aids Parkinson's disease (PD) diagnosis, with reduced caudate binding linked to cognitive decline.
• Vesicular monoamine transporter type 2 (VMAT2) imaging shows promise for detecting striatal changes in PD motor symptoms.
• This study investigates the hypothesis that lower VMAT2 caudate binding predicts future cognitive decline in PD.

Purpose of the Study:

• To evaluate the correlation between baseline VMAT2 and DAT caudate binding and subsequent cognitive decline in Parkinson's disease.
• To assess the sensitivity of VMAT2 and DAT imaging in predicting cognitive decline.
• To explore the relationship between VMAT2 and DAT binding in different brain regions (caudate and putamen) and cognitive changes.

Main Methods:

• Utilized clinical and imaging data from the Parkinson's Progression Markers Initiative (PPMI) cohort.
• Employed linear regression to analyze the relationship between baseline VMAT2/DAT caudate binding and changes in Montreal Cognitive Assessment (MoCA) scores.
• Performed secondary analyses on VMAT2/DAT binding in the putamen and categorized patients based on binding levels to compare clinical characteristics.

Main Results:

• Baseline VMAT2 caudate binding, but not DAT binding, significantly correlated with MoCA score changes (r=0.280, p=0.0164).
• Reduced VMAT2 caudate binding was associated with higher baseline motor severity and lower follow-up cognitive scores (p=0.0015).
• Patients with reduced VMAT2 caudate binding showed a significantly greater decline in MoCA scores compared to those with normal binding.

Conclusions:

• Reduced caudate VMAT2 binding may serve as a predictor of future cognitive decline in Parkinson's disease.
• VMAT2 caudate binding demonstrated higher sensitivity than DAT binding in predicting the magnitude of cognitive decline within this patient population.
• These findings highlight the potential of VMAT2 imaging as a valuable tool for monitoring cognitive progression in PD.